Leptomeningeal Disease Clinical Trial
Official title:
Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26)
To determine the safety of intrathecal (IT) PD1 antibody for Intrathecal application of PD1 antibody in metastatic solid tumors with leptomeningeal disease of solid tumors.
Leptmeningeal disease (LMD) is an aggressive subtype of metastatic disease in the central nervous system (CNS) and has a poor prognosis with a median overall survival of a few months.The IT-PD1 trial group wants to contribute to an improvement of this situation for LMD patients by using an intrathecal application route for the PD1 antibody, i.e. a drug that has shown clinical efficacy in the underlying tumor via the intravenous route. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT05414123 -
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
|
||
| Terminated |
NCT03711422 -
Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC
|
Phase 1 | |
| Recruiting |
NCT02422641 -
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
|
Phase 2 | |
| Active, not recruiting |
NCT03719768 -
Avelumab With Radiotherapy in Patients With Leptomeningeal Disease
|
Phase 1 | |
| Not yet recruiting |
NCT06146010 -
Non Interventional German Leptomeningeal Disease Register
|
||
| Active, not recruiting |
NCT03501979 -
Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD
|
Phase 2 | |
| Recruiting |
NCT05800275 -
Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease
|
Phase 2 | |
| Recruiting |
NCT04588545 -
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05809752 -
A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)
|
Phase 1 |